Trends in Metabolic and Bariatric Surgery Procedure Volume Recorded in MBSAQIP, 2015–2024
4 affiliations
- 1The University of Texas Southwestern Medical Center, Dallas, United States
- 2The University of Texas Health Science Center at Houston, Houston, United States
- 3HCA Florida Mercy Hospital, Miami, United States
- 4University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, United States
Abstract
Background: Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity; however, national procedure volume is not well characterized. We examined trends in MBS utilization in the United States from 2015 to 2024 using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP).
Methods: We conducted a repeated cross-sectional analysis of the 2015–2024 MBSAQIP Participant Use Data Files. Patients were classified as adolescents (10–18 years) or adults (≥ 19 years). Annual procedure volumes were analyzed separately by age group using segmented negative binomial regression with a prespecified change point at 2022 to estimate annual percentage changes during 2015–2022 and 2022–2024.
Results: A total of 1,970,021 patients completed MBS, including 1,964,090 adults and 5,931 adolescents. Sleeve gastrectomy was the most common procedure (61.8%), followed by Roux-en-Y gastric bypass (27.7%). Adult MBS utilization increased from 167,430 procedures in 2015 to 229,826 in 2022 before declining to 216,968 in 2023 and 176,915 in 2024. Adolescent utilization increased from 259 procedures in 2016 to 936 in 2023 before declining to 820 in 2024. Annual utilization increased significantly from 2015 to 2020 among both adults (p < 0.0001) and adolescents (P = 0.021) but declined significantly from 2022 to 2024 among adults (p < 0.001) and not adolescents (p = 0.98).
Conclusions: Annual MBSAQIP procedure volume increased through 2022 among adults and adolescents but declined in 2023–2024 only among adults. This emerging pattern warrants continued surveillance to determine whether it persists and to understand its implications for surgical access, treatment selection, and the delivery of obesity care.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11695-026-08962-1.
Related
- Does Sugammadex Decrease Length of Stay in Bariatric Surgery? Experience from an MBSAQIP Comprehensive Bariatric Center
- Tirzepatide for Weight Recurrence After Metabolic and Bariatric Surgery: A Critical Review of Direct and Indirect Evidence with Emphasis on Sleeve Gastrectomy, Nutritional Safety, and Clinical Implications
- Anti-Obesity Medications Versus Metabolic Bariatric Surgery as Pathways to Heart Transplant Eligibility in LVAD-Supported Patients: A Narrative Review
- Additive effects of metformin on glucose homeostasis after metabolic-bariatric surgery in nonobese insulin-deficient diabetic rats
- Hepatic metabolic reprogramming after metabolic and bariatric surgery: Gene-nutrition interactions and precision nutrition
BibTeX
@article{messiah2026trends,
title = {{Trends in Metabolic and Bariatric Surgery Procedure Volume Recorded in MBSAQIP, 2015–2024}},
author = {Sarah Messiah and Deepali Ernest and Mathew Matthew and Faisal Qureshi and Jackson Francis and Alicia Wheelington and Marlyn Allicock and Bethany Cartwright and Nestor de la Cruz-Muñoz and Steven Lipshultz and Ildiko Lingvay and Jaime Almandoz and Sarah Barlow},
journal = {Obesity Surgery},
year = {2026},
month = sep,
doi = {10.1007/s11695-026-08962-1},
url = {https://doi.org/10.1007/s11695-026-08962-1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Trends in Metabolic and Bariatric Surgery Procedure Volume Recorded in MBSAQIP, 2015–2024
AU - Sarah Messiah
AU - Deepali Ernest
AU - Mathew Matthew
AU - Faisal Qureshi
AU - Jackson Francis
AU - Alicia Wheelington
AU - Marlyn Allicock
AU - Bethany Cartwright
AU - Nestor de la Cruz-Muñoz
AU - Steven Lipshultz
AU - Ildiko Lingvay
AU - Jaime Almandoz
AU - Sarah Barlow
PY - 2026
DA - 2026/09/29
JO - Obesity Surgery
DO - 10.1007/s11695-026-08962-1
UR - https://doi.org/10.1007/s11695-026-08962-1
AB - Background: Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity; however, national procedure volume is not well characterized. We examined trends in MBS utilization in the United States from 2015 to 2024 using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP). Methods: We conducted a repeated cross-sectional analysis of the 2015–2024 MBSAQIP Participant Use Data Files. Patients were classified as adolescents (10–18 years) or adults (≥ 19 years). Annual procedure volumes were analyzed separately by age group using segmented negative binomial regression with a prespecified change point at 2022 to estimate annual percentage changes during 2015–2022 and 2022–2024. Results: A total of 1,970,021 patients completed MBS, including 1,964,090 adults and 5,931 adolescents. Sleeve gastrectomy was the most common procedure (61.8%), followed by Roux-en-Y gastric bypass (27.7%). Adult MBS utilization increased from 167,430 procedures in 2015 to 229,826 in 2022 before declining to 216,968 in 2023 and 176,915 in 2024. Adolescent utilization increased from 259 procedures in 2016 to 936 in 2023 before declining to 820 in 2024. Annual utilization increased significantly from 2015 to 2020 among both adults (p < 0.0001) and adolescents (P = 0.021) but declined significantly from 2022 to 2024 among adults (p < 0.001) and not adolescents (p = 0.98). Conclusions: Annual MBSAQIP procedure volume increased through 2022 among adults and adolescents but declined in 2023–2024 only among adults. This emerging pattern warrants continued surveillance to determine whether it persists and to understand its implications for surgical access, treatment selection, and the delivery of obesity care. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11695-026-08962-1.
SN - 0960-8923
SN - 1708-0428
ER -